Equity Details
Price & Market Data
Price: $2.94
Daily Change: -$0.53 / 18.03%
Daily Range: $2.89 - $3.46
Market Cap: $1,495,562
Daily Volume: 124,988
Performance Metrics
1 Week: -17.15%
1 Month: -77.59%
3 Months: -85.89%
6 Months: -92.65%
1 Year: -97.93%
YTD: -90.55%
About Jaguar Health, Inc. (JAGX)
A concise financial summary for Jaguar Health, Inc. (JAGX). Priced at 2.94, it shows a daily movement of -$0.53 / 18.03%. Market cap: 1,495,562. Performance over 1-week and 1-year are key takeaways.
Company Details
Employees: 47
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
